FAQ

VP025

 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2008-2008
01220082008

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2009
2009
A novel phospholipid-based drug formulation, VP025, modulates age- and LPS-induced microglial activity in the rat.
BACKGROUND A common change that occurs with age in the central nervous system is an increase in microglial-associated… (More)
Is this relevant?
2009
2009
The deficit in long-term potentiation induced by chronic administration of amyloid-beta is attenuated by treatment of rats with a novel phospholipid-based drug formulation, VP025.
Amyloid-beta (Abeta) peptides, the primary component of the amyloid plaques in Alzheimer's disease (AD), exert profound effects… (More)
  • figure 1
  • figure 2
Is this relevant?
2008
2008
Neuroprotective effects of novel phosphatidylglycerol-based phospholipids in the 6-hydroxydopamine model of Parkinson's disease.
Administration of VP025 (Vasogen Inc.), a novel drug formulation based on phospholipid nanoparticles incorporating… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2008
2008
Treatment with phosphotidylglycerol-based nanoparticles prevents motor deficits induced by proteasome inhibition: implications for Parkinson's disease.
Failure of the ubiquitin-proteasome system to degrade abnormal proteins may underlie the accumulation of alpha-synuclein and… (More)
Is this relevant?